METiS Technologies, a global leader in AI-driven nanodelivery innovation, announced the successful completion of its RMB 400 million Series D financing round. The announcement was made at the Zhongguancun (Daxing) Cell and Gene Therapy Industrial Park, a key hub for Beijing's life sciences sector.

Financing Co-led by Beijing Medical and Health Industry Investment Fund and Daxing Industrial Investment Fund

The Beijing Medical and Health Industry Investment Fund (Limited Partnership) is one of eight major industrial funds established with support from the Beijing Municipal Government. It focuses on innovative pharmaceuticals, advanced medical devices, and emerging technologies such as cell and gene therapy (CGT) and digital health. The fund plays a key role in accelerating the city's biotech innovation ecosystem.